Bioxcel Therapeutics Inc (BTAI)

Jul 26, 2025

How high can BioXcel Therapeutics Inc. stock price go in 2025Free Discussion Group - Metal.it

Jul 26, 2025

Jul 25, 2025

What analysts say about BioXcel Therapeutics Inc. stockFree Predictions - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Is BioXcel Therapeutics Inc. a good long term investmentBreakthrough capital growth - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

BioXcel Therapeutics Inc. Stock Analysis and ForecastSuperior investment outcomes - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Is BioXcel Therapeutics Inc. stock a good hedge against inflationBreakneck growth rates - jammulinksnews.com

Jul 25, 2025

Jul 23, 2025

What drives BioXcel Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional

Jul 23, 2025

Jul 22, 2025

BioXcel stock holds Buy rating at H.C. Wainwright ahead of FDA meeting - Investing.com Canada

Jul 22, 2025

Jul 22, 2025

BioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results - TipRanks

Jul 22, 2025

Jul 22, 2025

BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire

Jul 22, 2025

Jul 21, 2025

Bioxcel Therapeutics' Strategic Move to Expand IGALMI for At-Home Use: Assessing the Market Opportunity and Regulatory Pathway for First-in-Class Agitation Treatment in Outpatient Mental Health - AInvest

Jul 21, 2025

Jul 21, 2025

BioXcel schedules FDA meeting for IGALMI outpatient use expansion - Investing.com

Jul 21, 2025

Jul 21, 2025

BioXcel schedules FDA meeting for IGALMI outpatient use expansion By Investing.com - Investing.com Nigeria

Jul 21, 2025

Jul 21, 2025

BTAI files pre-sNDA to expand IGALMI label for home use | BTAI SEC FilingForm 8-K - Stock Titan

Jul 21, 2025

Jul 21, 2025

Bioxcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package In Support Of Potential Label Expansion For Igalmi - TradingView

Jul 21, 2025

Jul 21, 2025

First-Ever At-Home Agitation Drug: FDA to Review IGALMI for 23M Patient Market Opportunity - Stock Titan

Jul 21, 2025

Jul 16, 2025

why bioxcel therapeutics inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser

Jul 16, 2025

Jul 16, 2025

What makes BioXcel Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser

Jul 16, 2025

Jul 16, 2025

BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00 - AInvest

Jul 16, 2025

Jul 15, 2025

BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News - GuruFocus

Jul 15, 2025

Jul 15, 2025

BioXcel Therapeutics (BTAI) Gains Patent Approval, Price Target Affirmed | BTAI Stock News - GuruFocus

Jul 15, 2025

Jul 15, 2025

BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 15, 2025

BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent - Investing.com Nigeria

Jul 15, 2025

Jul 15, 2025

BioXcel Granted Patent for Dexmedetomidine Use - TipRanks

Jul 15, 2025

Jul 15, 2025

Why BioXcel Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - Newser

Jul 15, 2025

Jul 15, 2025

BioXcel wins USPTO nod; 14th Igalmi patent secures exclusivity to 2043 | BTAI SEC FilingForm 8-K - Stock Titan

Jul 15, 2025

Jul 15, 2025

How BioXcel Therapeutics Inc. stock performs during market volatilityProtected Capital Trading Plan - Newser

Jul 15, 2025